Examining a panel of melanocytic and melanoma cell lines, Tsavachidou et al. reported in 2004 that Spry2 acts as an inhibitor of ERK signaling in melanocytes and WT BRAF melanoma cells, but not in cell lines with BRAFV600E (previously designated as BRAFV599E) mutation [117]. Here, BRAF is linked to melanoma.